Javelin Pharmaceuticals, Inc. (JAV) posted fourth quarter net loss attributable to common stockholders of $8.1 million or $0.13 per share, compared to a net loss of $13.8 million or $0.23 per share in the year-ago quarter.
Total revenues for the quarter decreased to $301 thousand from $490 thousand in the last year quarter.
Analysts polled by Thomson Reuters expected the company to report a loss of $0.09 per share on revenues of $550.00 thousand. Analysts' estimates typically exclude special items.
For comments and feedback: editorial@rttnews.com